What is the Purpose of this Study?
Primary Objective: To evaluate the efficacy on hs-CRP reduction of different intravenous doses of CSL300 administered every 4 weeks. Primary Endpoint: The change from Baseline on the log scale in hs-CRP to Week 12.
Eligibility
- * \- Male or female at least 18 years of age
- * \- A diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks
- * \- Serum hs-CRP ≥ 2.0 mg/L
- * \- A diagnosis of diabetes mellitus OR ASCVD
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 2b / 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 in Subjects with End Stage Kidney Disease Undergoing Dialysis